The INCATE Selection Committee selected the new 6 ventures for Stage I support. Meet the new additions to the INCATE family:

A&J Science – A&J Science is leveraging its proprietary platform technology on marine natural products to develop highly effective antibiotics against hard-to-treat and intractable bacterial diseases.

Microplate Dx – Microplate Dx is an award-winning spinout company specialising in developing rapid antibiotic susceptibility testing diagnostics

Theralia AB – Theralia is developing the first oligonucleotide-based antibiotics, Therapeutic Oligonucleotides Activated by Nucleases (TOUCANs), for the targeted delivery of antibacterial molecules into infection area that enables a safer and more effective treatment for bacterial infections

Paralos Bioscience – Paralos Bioscience is developing a first-in-class phage-drug conjugate drug delivery platform technology with the goal of significantly improving the therapeutic index for drugs across many classes to tackle the most imminent global healthcare challenges

Omnicin Therapeutics – Omnicin Therapeutics is developing metal-containing inhalation therapies to resensitize multi-resistant bacteria to antibiotics”

Brigid Bio –  Providing next generation immunotherapy for life-threatening, invasive fungal infections.

Information on the other companies selected in previous stage I applications are on the portfolio page.